During tumor initiation and progression, cancer cells acquire a selective advantage, allowing them to outcompete their normal counterparts. Identification of the genetic changes that underlie these tumor acquired traits can provide deeper insights into the biology of tumorigenesis. Regions of copy number alterations and germline DNA variants are some of the elements subject to selection during tumor evolution. Integrated examination of inherited variation and somatic alterations holds the potential to reveal specific nucleotide alleles that a tumor "prefers" to have amplified. Next-generation sequencing of tumor and matched normal tissues provides a high-resolution platform to identify and analyze such somatic amplicons. Within an amplicon, examination of informative (e.g. heterozygous) sites deviating from a 1:1 ratio may suggest selection of that allele. A naïve approach examines the reads for each heterozygous site in isolation; however, this ignores available valuable linkage information across sites.
INTRODUCTION
Tumor development and growth can be viewed as an evolutionary process (Nowell 1976) . Genetic variation in the form of somatic alterations (e.g. mutations, translocations) and inherited polymorphisms provide the raw material for the acquisition of tumor related traits. Copy number aberrations (CNAs) -regions of somatic amplification (amplicons) or deletion -are a hallmark of tumor genomics. Recurrent amplicons have been observed over two decades (Kallioniemi et al. 1992; Joos et al. 1995; Cher et al. 4 In addition to CNAs, inherited polymorphisms are clearly related to cancer biology and predisposition. Classic examples include the highly penetrant mutations in BRCA1 (Hall et al. 1990; Miki et al. 1994) and BRCA2 (Wooster et al. 1995 ) that lead to breast cancer. More recently, genome-wide association studies (GWAS) have led to the discovery of more modestly penetrant variants that are associated with human traits (McCarthy et al. 2008; Hindorff et al. 2009; Witte 2010) , including cancer susceptibility (Amundadottir et al. 2006; Freedman et al. 2006; Zanke et al. 2007; Amos et al. 2008; Easton and Eeles 2008; Fletcher et al. 2008; Hung et al. 2008 ; Thorgeirsson et al. 2008; Ahmed et al. 2009 ; Le Marchand 2009; Song et al. 2009; Wu et al. 2009; Chung et al. 2010; Stadler et al. 2010a; Stadler et al. 2010b; Turnbull et al. 2010) .
GWASs stem partially from modern population genetics, which offers ample data and models to understand sequence polymorphisms -mostly single nucleotide variants (SNVs) -along with their correlation to one another and to disease phenotypes (Hartl and Clark 2007) . Specifically, the nonrandom allele combinations of proximal SNVs along a single genomic copy, called haplotypes, are a useful unit of local genomic variation. Although haplotypes are not observed directly from genotype data, computational phasing methods (Kimmel and Shamir 2005; Rastas et al. 2005; Eronen et al. 2006; Scheet and Stephens 2006; Browning and Browning 2007; Sun et al. 2007b ) distinguish maternal from paternal alleles, thus reconstructing germline haplotypes. Amplicons in cancer typically lie along a haplotype.
Since the somatic genome is a descendent of the germline genome, recent studies have explored the relationships between these distinct, but related genomes (Jones et al. 2009; Kilpivaara et al. 2009; Olcaydu et al. 2009 ). For example, a particular heterozygous locus in a tumor may "prefer" to have one germline allele somatically amplified over another. Such an event has been demonstrated in a targeted fashion in mouse skin tumors de Koning et al. 2007 ) and in human colorectal cancers (Ewart-Toland et al. 2003; Hienonen et al. 2006) . The latter studies found the AURKA gene to be preferentially amplified when containing a low penetrance (T > A) germline variant. In order to robustly perform this type of analysis genome-wide, allelic copy number status must first be measured; several 5 existing algorithms do this on SNP arrays (Nannya et al. 2005; Komura et al. 2006; Laframboise et al. 2007 ; Korn et al. 2008 ). We recently reported such an analysis and discovered new links between germline SNP variants within somatic amplicons in glioblastoma SNP array data LaFramboise et al. 2010) . The higher resolution, coverage, and larger dynamic range of NGS platforms now compel us to address such questions on tumor sequence data. As a first step, we must determine allelic copy number status of the reference alleles and SNVs within amplicons.
We present a novel method for analyzing NGS data in order to distinguish the amplified from the non-amplified alleles within tumor CNA regions, which themselves can be identified beforehand from the same data. We assume that only one of the chromosomes in a homologous pair undergoes amplification along an amplicon, as the majority of amplifications were observed to be mono-allelic versus bi-allelic in earlier work ). As we later show, the statistical signal for allelic imbalance of amplification that is coming from a single heterozygous site is often inconclusive due to limitations of coverage, sequencing bias, and stromal contamination. We therefore collate information from multiple heterozygous sites by leveraging the known structure of linkage disequilibrium (LD) between these variants within the population being interrogated. Specifically, we develop an HMM-based approach, called Haplotype Amplification in Tumor Sequences (HATS) , that reports the amplified alleles, and thus haplotypes, in the tumor sample based on: i) coordinates and copy number of CNA regions in a tumor sample called by existing methods, ii) allele-specific counts of reads from tumor and matched normal sequences (when available) corresponding to those regions ), iii) genotype calls of sites within those regions, and iv) independent training data consisting of phased haplotype sequences from the same population as that of the sample. This training data provides LD information across sites, allowing for more accurate haplotype construction versus examining each site in isolation. In contrast to prior work based on SNP array data , HATS is able to handle information unique to sequencing, such as rare or low frequency variants, including novel SNV sites or somatic mutations not represented in the training data. Evaluation of HATS using synthetic datasets as well as real tumor data, 6 obtained from The Cancer Genome Atlas (TCGA) (Network 2008) , emphasizes that HATS detects the amplified allele (within called amplicons) more accurately than an alternative, naïve approach over 99% of the time. The gain is especially prominent at lower to intermediate levels of average coverage, as well as in cases (including high coverage) involving stromal contamination or allelic bias.
RESULTS (EVALUATION)
For each heterozygous site within a called amplicon a (of copy number C a ) in a tumor sample, the naïve model compares the counts of reads that observe each allele and designates the allele with the greater read count as the amplified allele (see Methods). If the read counts are equal, no call is made. The naïve model is thus vulnerable to allele-specific biases in addition to fluctuations in read counts that occur at low coverage levels. HATS is designed to address these issues. HATS examines the allele-specific read depth and calculates allelic biases for each site within a, along with leveraging known LD structure over multiple sites (see Methods), to call the amplified alleles.
The advantage this provides HATS must be gauged. We summarize the performance of both the naïve model and HATS using the metric sensitivity, or the probability of a gold standard amplified allele at a heterozygous site being correctly called as amplified. We examine only those sites within regions known to be amplified, called a priori by a copy number calling algorithm or a different platform such as array CGH. Thus, specificity in this case -the fraction of non-amplified alleles called as non-amplifiedis identical to sensitivity. We first derive the power of the naïve model theoretically. Afterwards, we determine the sensitivity of the naïve model and HATS using simulated data, followed by real data.
Theoretical Power of the Naïve Model
The number of reads that cover each haploid copy of a site follows the Poisson distribution with genomewide expectation Λ. At a heterozygous site, Λ and
represent the mean read counts for the non-amplified and amplified alleles, respectively.
The combined mean for both alleles
7 the total probability of the amplified allele possessing a read count greater than that of the non-amplified allele, with the space of read count pairs generated from Poisson curves with respective means just mentioned. This is described more formally in Supplementary Methods. Results over a range of values for 2Λ and C a are shown in Supplementary Figure 1 .
Performance of HATS and the Naïve Model in Simulations
To measure the sensitivity of HATS across a variety of tumor dataset scenarios, we generated numerous synthetic datasets containing amplicons and assessed HATS' ability to call the amplified alleles within the amplicons. We performed the same for the naïve model as a baseline comparison. Simulations revealed that HATS' sensitivity eclipses that of the naïve model over 99% of the time in practical datasets.
In further detail, simulation of a particular dataset first requires training data consisting of phased germline genotypes for d unrelated individuals from the same population. We select n of the d individuals to comprise the test data (indexed by 1 ≤ j ≤ n). Stretches of somatic amplification are randomly generated and applied along the genome of each sample j such that these recurrent stretches overlap across the samples. Each CNA amplicon a in j thus consists of a gold standard amplified and non-amplified haplotype pair. For a heterozygous genotype at a site in a, counts of reads that observe the amplified allele and non-amplified allele are sampled from Poisson distributions with respective mean haploid coverages . In the scenarios that incorporate allelic bias (described later), these read counts may be adjusted to reflect the simulated bias.
For each sample j, the allele-specific read count information along each amplicon in j is analyzed by the naïve model. In addition, the training data of (d -n) samples, along with genotype information, copy number C a , tumor allelic read counts, and normal allelic read counts (for calculating bias) along
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Setting n > 1 is only relevant for scenarios in which allelic bias is simulated, as multiple samples provide a better estimate of the bias. When not simulating bias, we set n = 1 and employ a d-fold cross validation scheme in which each a in each j is processed by the naïve method and HATS, the latter using a training dataset of (d -1) samples. Again, overlapping amplicon coordinates are applied to each j.
The variability across the synthetic datasets is implemented via a set of seven parameters, described in Table 1 . We perform 100 trials for each parameter value combination when iterating over the parameter space, performing a d-fold cross validation per trial if n = 1. To prevent an explosive growth of the parameter space, we iterate over only one parameter at a time while maintaining the other parameters at their default values. The exception to this is when we simulate bias, in which we explore the space of the last two parameters, as described later below.
Towards determining sensitivity for a parameter value combination, we focus only on those accuracies (from the combination's trials) whose corresponding amplicons cover at least a threshold of v heterozygous sites. An example plot of accuracies for each amplicon a versus the number of heterozygous sites in a is depicted in Figure 1A (using example parameter values
Note that as the number of heterozygous sites in a increases, the accuracies converge to a peak for either method. The peak thus represents an asymptotic measure for accuracy, which we assign as the sensitivity. A large value for v isolates those points contributing to the peak while avoiding the discreteness effects observed in small values. To determine the value of each peak, we perform k-means clustering on those points passing v, setting k = 1 for each method. The resulting centroid for each method represents the peak and thus the sensitivity for that method.
Simulation Results
We obtained three training datasets from the 1000 Genomes Project (Consortium 2010) , each of which contained phased haplotype sequences from individuals from a HapMap population (Consortium 2005) .
9
Any trio children were removed to preserve independence among individuals, resulting in the datasets respectively including: d = 55 European (2 trio children removed), d = 55 Yoruban (1 trio child removed), and d = 59 Japanese and Chinese individuals. These datasets were used independently to avoid stratification effects. Data for additional individuals are expected to be available publicly over time. The HATS method, as well as the evaluation procedure above, can easily work with an expanded training set.
When simulating without bias, we observed that the first two parameters (regarding amplicon copy number and tumor haploid coverage) have the most impact on sensitivity. The fourth parameter, Mean Length of a Recurrent Amplicon, increases the number of heterozygous sites in a by virtue of increasing the span of a. We noted above that a longer a provides a better estimate of the asymptotic accuracy of each method. In Figure 1A , HATS performs better than the naïve method in over 99. The sensitivities of the two methods across varying levels of coverage (with a default copy number of 3) in the European individuals are depicted in Figure 1B . Both curves for HATS -with a Genotype Error Correction mechanism either enabled for low 2Λ j (to recover an allele possibly missed due to no reads observing that allele at low coverage, see Supplementary Methods) or disabledperform better than the naïve model, especially at intermediate to lower coverage levels. We also show that the naïve simulated sensitivity is congruent with its theoretical estimate. For both methods, the breakdown of sensitivities per read count observing a site over the coverage levels is given in 
Simulation Results: Modeling Biases
Real sequence data is known to contain bias, a common example of which is GC bias (Bentley et al. 2008; McKernan et al. 2009 ). While HATS' bias correction is designed to handle allele-specific biases in read counts in general, we test its ability to handle GC biases specifically. When simulating with bias, we vary the two parameters GC Read Bias Ratio and Number of Samples in Test Data. The resulting sensitivities are depicted in Figure 2A . The former parameter models GC bias by representing the ratio of AT reads versus GC reads at a heterozygous site. The greater the ratio, the stronger the induced bias; a value of 1.0 signifies no induced bias. Note this parameter only affects sites {G/A, G/T, C/A, C/T}. The latter parameter determines the test data size n, which when increased improves HATS' estimate of the bias and thus the performance.
The figure depicts the performance of the naïve model, HATS without bias correction (n = 1 is sufficient as n > 1 is relevant only when estimating bias), and HATS with bias correction. Our method consistently outperforms the naïve model. Furthermore, bias correction becomes more effective as either the level of induced bias or n increases. When the simulated bias is weak and n > 1, bias correction performs only slightly less than does no bias correction by a 0.003 cost in sensitivity. However, bias correction quickly gains the upper hand as the simulated bias increases past 1.5 (or 2 in the case of n = 2).
When n = 1, the estimate of bias is not as precise and results in a slightly weaker result (with a 0.008 sensitivity cost on average) unless the induced bias is very strong (3.33). Note that there is only a marginal performance improvement when increasing n from 15 to 20. The reasons are that the improvement in estimating the bias plateaus and that the training dataset size is reduced, which negatively impacts sensitivity. The latter reason may be assuaged with a larger d. In general, the figure demonstrates that HATS can accommodate and correct for stronger biases with the tradeoff of performing slightly weaker -a loss of 0.003 in sensitivity for n > 1 -for sites possessing smaller biases.
Simulation Results: Modeling Stromal Contamination
In tumor data, the called copy number of an amplicon often deviates from an integer quantity. The reasons are that the tumor cells may not all carry the same aberration (i.e. intra-tumoral genetic heterogeneity) and that a tumor sample may be admixed with normal cell types (i.e. stromal contamination). We focus on the latter reason. A region that is amplified in the tumor (with C a = 3) but copy neutral in the healthy somatic cells may average to a non-integer copy number, e.g. 2.50 in the case of a 50-50 mixture. We extend HATS to handle non-integer copy numbers and test its performance on simulated regions with C a = 2.50 and C a = 2.80, with the respective results shown in Figure 2B and
Supplementary Figure 5.
Note that as coverage reduces, the sensitivity of HATS is smaller than that from equivalent coverage levels with C a = 3. However, HATS maintains its gap over the naïve method.
More importantly, the naïve simulated and theoretical curves do not converge with HATS' curve even when coverage is high or very high (in the case of C a = 2.50), strongly suggesting that the naïve method performs inadequately in the common scenario of imperfect tumor purity. The breakdown of ( Figure 2B) sensitivities per read count observing a site over 2Λ j is depicted in Supplementary Figure 6 .
Simulation Results: Hemizygous Deletions with Stromal Contamination
We have extended HATS to analyze heterozygous deletion mixtures, in which deleted alleles are difficult to identify as lost due to the reads coming from the stromal cells that observe those alleles. HATS thus utilizes these read counts (along with LD structure) to identify these alleles (and haplotypes) as the ones lost in the tumor. HATS can analyze data with copy number between 1.5 and 2, exclusive. An example of simulation results (with C a = 1.9) is depicted in Supplementary Figure 7 . A potential future extension involves handling data with pure heterozygous deletions (C a = 1) when matched normal information is available; this functionality is already partially implemented via HATS' Genotype Error Correction feature. We do not focus on pure homozygous deletions, as the lost alleles may be recovered by examining the matched normal genotypes or via existing germline imputation algorithms (Browning and Browning 2007) . From this point onwards, we return to focusing on amplifications only.
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Performance of HATS and the Naïve Model in Real Data
We also evaluate the performance of both methods on CNA regions in real data. We consider data that has been sequenced as well as typed on an independent platform such as SNP arrays. The sequenced tumor data would be of high enough coverage  2 to accurately obtain genotype, copy number, and allele-specific read count information beforehand. For any amplicon a with C a ≥ 3, the amplified alleles that the naïve method calls within a are treated as the gold standard for a, as simulation results in Figure   1B reveal the naïve method's good performance at high coverage. Alternatively, the gold standard amplified alleles may be called from the SNP array using, for example, B-allele frequency differences (see Methods in for a detailed procedure and quality control filtering steps). In either case, we then down-sample a random fraction   / of the reads to mimic a dataset of lower coverage  2 , for which we test the of the amplified allele calling by HATS versus the naïve method.
Call accuracy for  2 is reported as the fraction of correct calls across 100 such sub-sampling trials.
Performance is demonstrated in a glioblastoma tumor sample (TCGA-06-0877) of European descent, with whole genome sequence, array CGH, and SNP array data obtained from The Cancer
Genome Atlas (Network 2008 ) (see Acknowledgments). Chromosomes 2, 7, 12, 19, and 20 of this sample are called by array CGH as possessing a chromosome-wide average copy number of 2.6, suggesting a tumor copy number of 3 with up to 40% of sample cells being non-tumor related cells of copy number 2. We considered a specific CNA region at chr19:2.18-2.54Mb that is reported to possess a local average coverage of  2 = 33.7 and a local average copy number of C a = 3.18, consistent with a local copy number of 4 in the 60% of sample cells that are tumor cells. Figure 3 presents call accuracy for this region across various levels of coverage  2 , with the gold standard amplified alleles called by the naïve method on the tumor sequence data itself. As expected, both naïve calling and HATS perform well when  2 is high. As  2 decreases, the performance gap between HATS and the naive method widens before shrinking slightly at low coverage. Utilizing the Genotype Error Correction, however, 13 increases the performance. The breakdown of sensitivities per read count observing a site at  2 is depicted in Supplementary Figure 8 .
We ran this down-sampling analysis again, except with the gold standard amplified alleles called from the SNP array data for the same sample. SNP arrays naturally possess a lower density of sites interrogated as compared to sequence data. Restricting HATS to only array sites forces it to ignore sites in the training data not typed on the array, resulting in weaker LD structure gleaned from the training data. Despite this, HATS retains its performance gain over the naïve curve, as seen in Supplementary   Figure 9 . Moreover, only three heterozygous sites comprise the gold standard after quality control filtering in this case; HATS performed better than the naïve method even with such few sites.
We consider another region at chr2:30-31Mb within the same sample possessing local
38.7 and C a = 2.50 (50% stromal contamination). We discuss findings in Supplementary Results, with HATS' markedly superior sensitivity illustrated in Supplementary Figures 10 and 12 . These evaluation procedures reveal that HATS outperforms the naïve model in real tumor data, even when sites are few and especially when coverage is reduced or stromal contamination is present.
DISCUSSION
During recent years, algorithms had been developed for SNP array platforms to determine somatic allelespecific copy numbers of germline SNPs. Such data indicates CNAs and enables one to pinpoint potential disease-associated variants, and by virtue haplotypes, within the wide span of these regions.
However, the drawbacks of these algorithms are the suboptimal resolution of the platform, and more importantly, issues with call fidelity: amplified regions render these algorithms prone to incorrect genotype calls in tumor tissue. As NGS technologies offer nucleotide level resolution while avoiding SNP array issues that affect amplified call fidelity, we aimed to develop a novel method that could determine the amplified alleles and thus haplotypes in such data. To our knowledge, no other methods exist that call somatically amplified alleles and haplotypes in NGS data.
14 Determination of haplotypes is equivalent to locally phasing the tumor data using read counts from the tumor sample and haplotype frequencies from training data. Only one chromosome is assumed to be amplified along a homologous region. At its core, HATS builds an HMM, using allele-specific read counts as emissions and training haplotypes to model transitions. Usage of the training data is motivated by the notion that the haplotype constructed from the amplified alleles (called within an amplicon) should partially reflect a mosaic of existing haplotypes within the same population. The training haplotypes enable HATS to utilize linkage information from multiple sites, thus helping to improve power over that of the naïve method. Within an amplicon a called a priori, HATS reports the amplified allele at each site that is polymorphic either in the sample or the training data, including those sites harboring rare variants or somatic mutations. We note that HATS is also able to handle hemizygous deletion mixtures. It can identify the deleted alleles or haplotypes that are otherwise difficult to identify as deleted (due to traces of those alleles coming from contaminating stromal cells). The design philosophy of HATS envisions the algorithm as a tool in a workflow of algorithms for studying tumors, helping to open the door for allele-specific downstream analysis. At the same time, it is reliant on upstream data; namely, the a priori calling of the amplicon. This is done intentionally, as modularity is a fundamental design principle in building complex pipelines, and it guides us here as well.
Furthermore, CNA and CNV calling has been studied extensively and has matured over the years to the point that it has become integral to existing pipelines (Network 2008; Network 2011 ). However, upstream errors can occur, some of which are safeguarded by HATS. For example, small errors in input amplicon copy number have little effect on HATS, which can naïvely validate copy number using tumor and matched normal read counts. The effect is further reduced due to the power HATS leverages from the training data. Other errors include amplicons that are a result of platform-specific biases (e.g. PCR bias). These can be caught by HATS' bias correction if they are allele-specific and appear in the matched normals as well. In addition, the power from the training data can help reduce the effect of spurious PCR biases that may occur within an amplicon span. The naïve method, on the other hand, would be much more vulnerable to this. Other errors include inexact a priori amplicon breakpoint prediction, which could especially occur with the low resolution of arrays. Such errors may result in: HATS calling an allele as amplified even if the site lies outside the amplicon in truth, or sites being ignored by HATS if in truth they lie within the amplicon boundary. However, some of these effects are mitigated when studying multiple tumors downstream. Amplicons due to artifact in one sample will likely not recur over multiple tumors and may thus be identified as unique or erroneous. Similarly, testing for recurrence will tease out amplicons under selection versus passenger amplicons that occur randomly and propagate due to duplication mechanisms or genomic instability during tumor evolution.
A possible alternative to HATS entails first computationally phasing the matched normal sequence (and by virtue, the tumor sequence), ignoring valuable read count information during phasing.
One might then assess tumor read counts at several sites within an amplicon to determine the particular phased haplotype targeted for amplification. We tested this approach on four regions from the glioblastoma patient (TCGA-06-0877), three of which lie on chromosome 2 and the last on chromosome 19 (see Supplementary Table 1) . Only sites common to both the sequence data and SNP array were considered. The gold standard amplified alleles were determined using array calls. HATS performed with equal or greater accuracy on all four regions, while inaccuracies in phasing-first indicated switch error. These results support HATS' relevance to amplified allelic calling. Another advantage that HATS possesses over phasing-first is the ability to make calls on rare variants or somatic mutations using read depth information. Phasing algorithms, which also rely on germline training data, seem underpowered to do this. In addition, HATS may recover heterozygous calls at low coverage via its Genotype Error Correction; performing the same with a germline phasing algorithm for sequence data would require extra pre-processing overhead for the end user. Furthermore, several phasing algorithms assume HardyWeinberg equilibrium in the test data, which may not always be the case due to the presence of risk alleles (Marchini et al. 2006) . Thus, phasing the tumor via the matched normal may not always lead to accurate results. On the contrary, as the constructed tumor haplotype would reflect the genome order of the reference sequence and matched normal as mentioned above, HATS could potentially be used to phase the germline alleles in the matched normal sample based on the tumor data.
One potential future avenue involves examining haplotypes within recurrent CNA regions across tumor samples to reveal such genes. This was performed previously on SNP arrays at the single SNP level LaFramboise et al. 2010) and can now be extended to next generation sequencing data. HATS' reporting of the amplified allele may serve as a first step in this downstream analysis possibility. One benefit is that sites that were not typed on SNP arrays may be revealed to be selectively amplified across tumors in sequence data. In addition, the improved call fidelity as compared to amplified allelic calls on SNP arrays may lead to more robust results.
More generally, the HATS algorithm is designed to call allelic imbalances (AIs) at genomic sites within a sample. AIs can provide important information in multiple scenarios. For example, AI in transcripts has been detected by RNA sequencing. Transcripts demonstrating this phenomenon have genetic or epigenetic influences driving this difference Heap et al. 2010; Tuch et al. 2010) . Chromatin immunoprecipitation followed by high-throughput sequencing, ChIP-seq, can also reveal AI at heterozygous sites. In this context, allelic imbalance can reflect differential binding specificity of a particular DNA-protein interaction, thereby possibly highlighting functional variants.
In the pursuit of detecting causal or associated variants, it aids the cancer community to integrate somatic and germline DNA changes. We present a method that helps move towards this end in next generation tumor sequence data. The strong evaluation of HATS provides us confidence to offer the community this powerful local phasing method. We hope that cancer researchers will find it beneficial towards discovering variants and potential oncogenes.
METHODS

Naïve Model Parameters and Input Data Specifications
We denote the read count for allele x  {0, 1} at a genomic site i (a potential SNV site) in the tumor , it is meaningful to ask which allele is amplified. A naïve model for calling the amplified allele would simply choose the allele for which a greater number of reads is observed, denoted as arg-max x {r x }. A call is avoided in case of a tie.
With a probabilistic view in mind, r x is a value of a random variable R x ~ Poisson(λ x ), where λ x represents the site-, individual-and allele-specific expectation for the number of tumor reads. This formulation interprets the naïve call as choosing the allele for which the maximum likelihood estimate of λ x is greater. This model makes use of no input data other than r x and calls sites along the amplicon a independently of one another. It thus serves as a suitable performance baseline against HATS.
HATS Model Parameters
The contribution of this manuscript involves recovering the amplified allele based on a more careful modeling of λ x . Specifically, λ 0 and λ 1 are assumed to be proportional to the number of copies of the respective alleles at site i in the tumor sample j at hand. We denote these numbers, or tumor genotype calls, by G 0 and G 1 , respectively. The total copy number
at site i is greater than two in an amplicon a, and our task of identifying the amplified allele is tantamount to distinguishing between the
. Furthermore, λ x is assumed to be proportional to Λ, the average haploid coverage of the sequenced tumor j; Λ is a sample-specific quantity that depends on the sequencing resources invested in the data for that tumor. Lastly, NGS reads are known to be often biased towards particular nucleotides (Bentley et al. 2008; McKernan et al. 2009 ). Therefore, a realistic and general model for λ x needs to account for such a site-specific (versus sample-specific) phenomenon.
Our model then assumes this parameter is proportional to an allelic bias factor b x local to this site. In summary, including site-and sample-specific subscripts (i, j) for completeness of the formal equation: Read counts x r for normal samples are analogously defined, as are the random variables:
Poisson R  , where
, and:
The genotype call at a site is in fact comprised of the haplotype calls at that site. We aim to distinguish the two haploid copies of the genome giving rise to the tumor genotype call. Within an amplicon a, we assume one of the haplotypes is (A)mplified while the other is (U)n-amplified . We formally represent these ground truth haplotypes as binary strings ; this is depicted in Figure 4A . Naturally, the tumor genotype call for an amplified allele x sums the copies on both haplotype calls, with amplification of a particular haplotype call represented by multiplication with a constant (C a -1) :
The tumor genotype call for a non-amplified allele x is similar:
For the matched normal, the genotype call sums the copies of two non-amplified haplotype calls, as per the requirements of copy neutrality (see Figure 4A ):
HATS Hidden Markov Model
We use an accepted model of human variation (Kimmel and Shamir 2005; Rastas et al. 2005; Eronen et al. 2006; Browning and Browning 2007; Sun et al. 2007b) , presenting haplotypes 
Haplotype HMM
In detail, the haplotype HMM y V is a state machine with probabilistic transitions and deterministic emissions. The states and transitions follow the haplotype models used by computational phasing algorithms for SNP array data (Kimmel and Shamir 2005; Rastas et al. 2005; Eronen et al. 2006; 21 Browning and Browning 2007; Sun et al. 2007b) . In a similar vein, we locally phase the tumor sequence data based on read counts in the sample data and haplotype counts in population-relevant training data. . The concept behind this is that at a given locus, a germline haplotype of a tumor sample is assumed to be identical to one of the training haplotypes, randomly switching the training sample that is locally identical to the tumor haplotype along the genome. This concept is a standard in germline genetics (Stephens et al. 2001; Scheet and Stephens 2006; Browning and Browning 2007) . The candidate haplotype label of s is thus tested for such a local matching. We enforce The transition probability between consistent states ŝ and s is set as a Dirichlet prior based on
Pr(
The function freq() represents the haplotype frequency of 
Genotype HMM
We construct a genotype HMM V by cross-multiplying V A and V U (see Figure 4D) . The M time points remain unchanged. At a given t, the set of states is the Cartesian product Assuming C a is known beforehand and that b x is calculated, parameters G x and λ x can be calculated from y x H (over all y and x). The emission probability for s is the probability of observing r x , assuming an underlying Poisson distribution for the read counts at site i t with mean λ x . It is calculated on the Poisson distribution as:
HMM Deciphering Algorithm to Call the Amplified Allele
The ultimate goal of the HMM is to decipher which allele x is amplified at t. Towards this end, we apply 
HATS finally reports the most likely such x to have been amplified at t via: arg-max x {L t (x)}. In the case of a tie, HATS designates  as the amplified allele at t to reflect this ambiguity.
Input Data Specifications
HATS jointly considers input regarding n tumor and matched normal samples (1 ≤ j ≤ n). Specifically, input data corresponding to a particular sample j includes the input data from the naïve model, in addition to: 1) C a (> 2, obtained by preprocessing with a copy number calling algorithm (Chiang et al. 2009 ) or typing the sample on another platform, e.g. array CGH)
2) Λ and  (calculable beforehand)
3) x r and x G for all i in each of the n samples that are copy neutral at i, with the constraint that i resides in amplicon a in sample j 4) Genotypes from the tumor of individual j that do not take copy number into account
The latter two are obtainable via a genotype caller component from an alignment algorithm ). The third input specification -read counts from each i within copy neutral regions in tumor and matched normal samples, such that i resides in an amplicon in at least one of the n input tumor samples -allows for calculation of the site-specific bias factor b x . Estimation of b x and the effects of the availability of matched normal data on this estimation are discussed in Supplementary Methods.
Lastly, HATS takes advantage of linkage information across multiple sites to call the amplified alleles, whereas the naïve model ignores LD by examining each site individually. Towards this end, HATS uses training data (denoted above as D) for human germline variation, which entails phased haplotype sequence data on d unrelated individuals that are independently sampled from the same population as the n cancer patients whose tumors are to be analyzed. The training population can be determined as a preprocessing step using ancestry informative markers in the tumor samples. The training data itself can be obtained, for example, from the 1000 Genomes Project (Consortium 2010) .
Enhancements and Optimizations
Tumor samples may include sites housing somatic mutations or variants that are unique to the samples and missing in the training data (e.g. singletons). HATS utilizes read depth, along with bias determination, to call the amplified allele at each such site. In addition, HATS possesses the ability to potentially recover an allele missed due to low coverage (Genotype Error Correction); this is integrated with a mechanism to utilize tumor genotypes to prune the explosive growth of states. Details on these enhancements are provided in Supplementary Methods.
Availability
The HATS source code, as well as instructions to build and run the software, is available at (http://tumorhats.sourceforge.net/).
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27
FIGURES
TABLES
Parameter Name Default Description
Amplicon Copy Number ( 
Mean Length of a Recurrent Amplicon
390kb This parameter represents the mean of an exponential distribution, which upon sampling determines the length of recurrent amplicons across samples. The distribution possesses a mean of 390kb by default. This exponential distribution can produce stretches of over 1 or even 2 Mb. The default value was determined in .
Number of Recurrent Amplicons
5
This parameter determines the number of recurrent amplicons in the genome. A value of 5 represents a realistic number of such regions, as was determined in .
GC Read Bias Ratio 1.0
This parameter is used to represent GC bias that is observed in real sequence data. It represents the ratio of the simulated AT read count to the simulated GC read count at the site i in question. The idea is that the presence of a G or C at i translates to a (slightly) higher GC content level, which may disrupt the sequencing chemistry and thus induce bias. A value of 1.0 indicates no bias, while larger values indicate stronger bias. The default value is set to 1.0 so that other parameters can be tested independently of bias during simulation.
Number of Samples in Test Data
1
This parameter represents the number of samples that are to be excised from the training dataset in order to be used as test data. For example, if the original training dataset contained ten individuals, and this parameter was set to 2, then two individuals would comprise the test data while eight would comprise the effective training data to be used in the simulations. The default value is set to 1, as values > 1 are only relevant when simulating with bias. Increasing the test data size in bias simulation improves HATS' estimation of the bias.
